NASDAQ:FMI - Foundation Medicine Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$136.70 +0.30 (+0.22 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$136.70
Today's Range$136.40 - $136.70
52-Week Range$31.70 - $137.20
Volume1.23 million shs
Average Volume873,167 shs
Market Capitalization$5.05 billion
P/E Ratio-30.38
Dividend YieldN/A
Beta-0.04
Foundation Medicine logoFoundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.

Receive FMI News and Ratings via Email

Sign-up to receive the latest news and ratings for FMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FMI
CUSIPN/A
Phone617-418-2200

Debt

Debt-to-Equity Ratio4.76
Current Ratio2.27
Quick Ratio1.98

Price-To-Earnings

Trailing P/E Ratio-30.38
Forward P/E Ratio-31.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$152.90 million
Price / Sales33.12
Cash FlowN/A
Price / CashN/A
Book Value$0.87 per share
Price / Book157.13

Profitability

EPS (Most Recent Fiscal Year)($4.50)
Net Income$-161,460,000.00
Net Margins-84.96%
Return on Equity-299.63%
Return on Assets-94.81%

Miscellaneous

Employees662
Outstanding Shares37,040,000

The Truth About Cryptocurrencies

Foundation Medicine (NASDAQ:FMI) Frequently Asked Questions

What is Foundation Medicine's stock symbol?

Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."

How were Foundation Medicine's earnings last quarter?

Foundation Medicine Inc (NASDAQ:FMI) posted its quarterly earnings results on Wednesday, May, 2nd. The company reported ($1.02) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.10) by $0.08. The company had revenue of $52.84 million for the quarter, compared to the consensus estimate of $44.99 million. Foundation Medicine had a negative net margin of 84.96% and a negative return on equity of 299.63%. The firm's revenue was up 100.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.31) EPS. View Foundation Medicine's Earnings History.

When is Foundation Medicine's next earnings date?

Foundation Medicine is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Foundation Medicine.

What price target have analysts set for FMI?

4 Wall Street analysts have issued 12 month price objectives for Foundation Medicine's stock. Their forecasts range from $73.00 to $90.00. On average, they anticipate Foundation Medicine's stock price to reach $81.00 in the next year. View Analyst Ratings for Foundation Medicine.

Who are some of Foundation Medicine's key competitors?

Who are Foundation Medicine's key executives?

Foundation Medicine's management team includes the folowing people:
  • Mr. Alexis Borisy, Co-Founder, Founding Advisor & Independent Director (Age 46)
  • Mr. Troy Cox, CEO, Pres & Director (Age 54)
  • Mr. Jason Ryan, CFO & Principal Accounting Officer (Age 44)
  • Mr. Konstantin Fiedler, Chief Operating Officer (Age 52)
  • Mr. Tom Godden, Chief Information Officer

Has Foundation Medicine been receiving favorable news coverage?

News articles about FMI stock have been trending positive this week, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foundation Medicine earned a news impact score of 0.26 on Accern's scale. They also gave news headlines about the company an impact score of 46.04 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Foundation Medicine's major shareholders?

Foundation Medicine's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.71%), Lord Abbett & CO. LLC (1.66%), Baillie Gifford & Co. (1.05%), Amundi Pioneer Asset Management Inc. (0.74%), Elk Creek Partners LLC (0.37%) and Highbridge Capital Management LLC (0.29%). Company insiders that own Foundation Medicine stock include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine.

Which institutional investors are selling Foundation Medicine stock?

FMI stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, BlackRock Inc., Pier Capital LLC, Platinum Investment Management Ltd., Employees Retirement System of Texas, A.R.T. Advisors LLC, California Public Employees Retirement System and DekaBank Deutsche Girozentrale. Company insiders that have sold Foundation Medicine company stock in the last year include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Insider Buying and Selling for Foundation Medicine.

Which institutional investors are buying Foundation Medicine stock?

FMI stock was acquired by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, Highbridge Capital Management LLC, PointState Capital LP, Franklin Resources Inc., Baillie Gifford & Co., UBS Group AG, Trexquant Investment LP and Lord Abbett & CO. LLC. View Insider Buying and Selling for Foundation Medicine.

How do I buy shares of Foundation Medicine?

Shares of FMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foundation Medicine's stock price today?

One share of FMI stock can currently be purchased for approximately $136.70.

How big of a company is Foundation Medicine?

Foundation Medicine has a market capitalization of $5.05 billion and generates $152.90 million in revenue each year. The company earns $-161,460,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Foundation Medicine employs 662 workers across the globe.

How can I contact Foundation Medicine?

Foundation Medicine's mailing address is 150 Second Street, Cambridge MA, 02141. The company can be reached via phone at 617-418-2200 or via email at [email protected]


MarketBeat Community Rating for Foundation Medicine (FMI)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  438
MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe FMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.